company background image
VERU

Veru NasdaqCM:VERU Stock Report

Last Price

US$22.25

Market Cap

US$1.8b

7D

93.5%

1Y

226.2%

Updated

16 Aug, 2022

Data

Company Financials +
VERU fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

VERU Stock Overview

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers.

Veru Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Veru
Historical stock prices
Current Share PriceUS$22.25
52 Week HighUS$23.99
52 Week LowUS$4.34
Beta-0.40
1 Month Change29.14%
3 Month Change48.24%
1 Year Change226.25%
3 Year Change1,115.85%
5 Year Change1,466.90%
Change since IPO235.85%

Recent News & Updates

Aug 10

Veru Q3 2022 Earnings Preview

Veru (NASDAQ:VERU) is scheduled to announce Q3 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.15 (-400.0% Y/Y) and the consensus Revenue Estimate is $17.08M (-3.3% Y/Y). Over the last 1 year, VERU has beaten EPS estimates 25% of the time and has beaten revenue estimates 75% of the time. Over the last 3 months, EPS estimates have seen 0 upward revisions and 3 downward. Revenue estimates have seen 0 upward revisions and 3 downward.

Aug 03

Veru updated analysis on COVID treatment sabizabulin will lead to EUA - Oppenheimer

Oppenheimer said that a new analysis conducted by Veru (NASDAQ:VERU) on mortality rates in a phase 3 trial of its COVID-19 therapy sabizabulin assuages concerns and will lead to an Emergency Use Authorization from the U.S. FDA. The firm cited a new corporate presentation in making its call. The document indicates that the primary endpoint -- mortality rate by day 60 -- was met. In the treatment group, it was 20.2%, while in the placebo group, 45.1%. Sabizabulin also met second efficacy endpoints compared to placebo in terms of days in the ICU, on mechanical ventilation, and in the hospital. Read what Jefferies had to say in July about the prospects for sabizabulin.

Jul 25

Veru eligible for expedited review in U.K. for COVID-19 therapy

Clinical-stage biotech Veru (NASDAQ:VERU) announced on Monday that U.K. regulators agreed that the currently available safety and efficacy data for its experimental COVID-19 therapy sabizabulin would support an expedited review for a marketing application. The U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) has issued this view in relation to a potential marketing authorization application for the oral drug in hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS). “With this decision, we plan to proceed toward the submission of our application as soon as possible,” Veru’s (VERU) Chief Executive Officer Mitchell Steiner noted. In June, the company announced it sought the FDA’s emergency use authorization for sabizabulin as a treatment for hospitalized COVID-19 patients who are at risk of ARDS.

Shareholder Returns

VERUUS Personal ProductsUS Market
7D93.5%2.0%3.6%
1Y226.2%-18.1%-9.6%

Return vs Industry: VERU exceeded the US Personal Products industry which returned -18.1% over the past year.

Return vs Market: VERU exceeded the US Market which returned -9.6% over the past year.

Price Volatility

Is VERU's price volatile compared to industry and market?
VERU volatility
VERU Average Weekly Movement17.7%
Personal Products Industry Average Movement10.7%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: VERU is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.

Volatility Over Time: VERU's weekly volatility has decreased from 30% to 18% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1971252Mitch Steinerhttps://www.verupharma.com

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer.

Veru Inc. Fundamentals Summary

How do Veru's earnings and revenue compare to its market cap?
VERU fundamental statistics
Market CapUS$1.78b
Earnings (TTM)-US$47.05m
Revenue (TTM)US$52.41m

34.0x

P/S Ratio

-37.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VERU income statement (TTM)
RevenueUS$52.41m
Cost of RevenueUS$10.02m
Gross ProfitUS$42.40m
Other ExpensesUS$89.44m
Earnings-US$47.05m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.59
Gross Margin80.89%
Net Profit Margin-89.77%
Debt/Equity Ratio12.5%

How did VERU perform over the long term?

See historical performance and comparison